Antimetastatic Activities and Mechanisms of Bisdioxopiperazine Compounds

Author(s): Da-Yong Lu, Ting-Ren Lu

Journal Name: Anti-Cancer Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Anti-Cancer Agents)

Volume 10 , Issue 7 , 2010

Become EABM
Become Reviewer
Call for Editor


Bisdioxopiperazine (Biz) compounds, including ICRF-154 and razoxane (ICRF-159, Raz), are anticancer agents developed in the UK specifically targeting tumor metastases. Further three bisdioxopiperazine derivatives, bimolane (Bim), probimane (Pro) and MST- 16, have been synthesized at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, PR China after 1980. Since metastases, the prevailing deadliest pathologic feature of cancer in clinics, have been the main obstacle in cancer therapy, antimetastatic effects and mechanisms of Biz compounds are interesting and significant topics of all time for researchers undergoing the investigations of metastases biology, treatments and patho-physiology. This review addresses and highlights the different inhibitions against metastases in vivo and molecular mechanisms in vitro of Biz compounds especially relating to the inhibitions of tumor metastasis including pathways of inhibitions against angiogenesis, topoisomerase II, calmodulin, sialic acid, fibrinogen, cell-movement and so on. We argue hererin that the systematic exploration of antimetastatic activity and mechanisms of Biz compounds seems to be a shortcut for a final solution of cancer therapy in the future.

Keywords: Bisdioxopiperazine compounds, probimane, razoxane, antineoplastic drugs, antimetastatic drugs, angiogenesis, spontaneous metastases, calmodulin, sialic acids, fibrinogen, cell-movement.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2010
Page: [564 - 570]
Pages: 7
DOI: 10.2174/187152010793498654
Price: $65

Article Metrics

PDF: 9